Skip to main content

Table 3 Cox proportional hazard analyzes for OS after CBZ treatment

From: The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients

  Univariate Multivariate Multivariate (Stepwise)
  Odds ratio (95% CI) P Odds ratio (95% CI) P Odds ratio (95% CI) P
Age (y) > 70 1.14 (0.64–2.04) 0.654     
PS ≥ 1 3.14 (1.63–6.04) 0.001* 1.43 (0.55–3.73) 0.461   
GS ≥ 9 1.07 (0.58–2.00) 0.827     
PSA (ng/ml) > 100 2.55 (1.41–4.58) 0.002* 2.35 (1.07–5.18) 0.034* 2.84 (1.33–6.03) 0.007*
Hb (g/dl) < 12 1.95 (1.03–3.72) 0.042* 2.03 (0.80–5.15) 0.136 2.50 (1.09–5.73) 0.030*
LDH (U/L) > 300 2.03 (1.10–3.74) 0.023* 1.08 (0.45–2.60) 0.864   
ALP (U/L) > 350 1.98 (1.07–3.67) 0.030* 1.98 (0.83–4.69) 0.122   
Bone meta at diagnosis 1.00 (0.55–1.81) 0.998     
Time to CRPC (y) < 1 1.42 (0.79–2.54) 0.238     
DTX cycle< 10 1.81 (0.95–3.43) 0.071     
ABI or ENZA 1.66 (0.76–3.60) 0.201     
Low Initial CBZ dose 2.22 (1.11–4.43) 0.023* 2.15 (0.48–9.76) 0.32 2.81 (1.11–7.13) 0.030*
RDI 60% or lower 2.76 (1.24–6.17) 0.013* 1.26 (0.36–4.34) 0.717   
  1. PS performance status, DTX docetaxel, ABI abiraterone, ENZ enzalutamide
  2. RDI:relative dose intensity, *P < 0.05